Related references
Note: Only part of the references are listed.Progress in the treatment of gastric cancer in Japan over the last 50 years
Mitsuru Sasako
ANNALS OF GASTROENTEROLOGICAL SURGERY (2020)
Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial
Atsuo Takashima et al.
GASTRIC CANCER (2019)
A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naive patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial
Kazuhiro Nishikawa et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial
Kazuhiro Yoshida et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study
Seiichiro Mitani et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy
Yoshiaki Nakamura et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial
Kazuhiro Nishikawa et al.
GASTRIC CANCER (2018)
Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer
Shingo Kanaji et al.
ANNALS OF GASTROENTEROLOGICAL SURGERY (2018)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
The Efficacy of Taxanes- and Oxaliplatin-Based Chemotherapy in the Treatment of Gastric Cancer After D2 Gastrectomy for Different Lauren Types
Zhen Zheng et al.
MEDICINE (2016)
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
Sung Hoon Noh et al.
LANCET ONCOLOGY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis
Kohei Shitara et al.
GASTRIC CANCER (2012)
Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1
Toru Aoyama et al.
GASTRIC CANCER (2011)
Japanese classification of gastric carcinoma: 3rd English edition
GASTRIC CANCER (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
Wasaburo Koizumi et al.
LANCET ONCOLOGY (2008)
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
Shinichi Sakuramoto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Share Paper
